Moderna Inc

Common Name
Moderna
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
5,800
Ticker
MRNA
Exchange
NASDAQ/NGS
Description
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vac...

Financial Statements of Moderna

Below are the financial statements of Moderna, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in billions of USD202420232022
Revenue
Net product sales
3.11a
6.67a
18.44a
Other revenue
0.13a
0.18a
0.83a
Total revenue
3.24a
6.85a
19.26a
Operating expenses
Cost of sales
-1.46a
-4.69a
-5.42a
Research and development
-4.54a
-4.85a
-3.3a
Selling, general and administrative
-1.17a
-1.55a
-1.13a
Total operating expenses
-7.18a
-11.09a
-9.84a
(Loss) income from operations
-3.95a
-4.24a
9.42a
Interest income
0.43a
0.42a
0.2a
Other expense, net
-0.09a
-0.12a
-0.05a
(Loss) income before income taxes
-3.61a
-3.94a
9.58a
(Benefit from) provision for income taxes
-0.05a
0.77a
1.21a
Net (loss) income
-3.56a
-4.71a
8.36a

Verified Sources Behind Moderna’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Moderna’s data sources below and access millions more through our Disclosure Search.

a. Moderna's Annual Report 2024
Trace every data point back to Moderna’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?